Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label …
…, ZD Liu, S Xu, KN Chen, SD Xu, LX Liu… - The Lancet …, 2018 - thelancet.com
Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …
[HTML][HTML] Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 …
…, ZD Liu, S Xu, KN Chen, SD Xu, LX Liu… - Journal of clinical …, 2021 - ncbi.nlm.nih.gov
METHODS From September 2011 to April 2014, 222 patients from 27 sites were randomly
assigned 1: 1 to adjuvant gefitinib (n= 111) or VP (n= 111). Patients with resected stage II-IIIA (…
assigned 1: 1 to adjuvant gefitinib (n= 111) or VP (n= 111). Patients with resected stage II-IIIA (…
[HTML][HTML] Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
…, ZD Liu, S Xu, KN Chen, SD Xu, LX Liu… - Nature …, 2021 - nature.com
The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over
chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung …
chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung …
Cardiopulmonary exercise testing screening and pre‐operative pulmonary rehabilitation reduce postoperative complications and improve fast‐track recovery after …
K Gao, P Yu, J Su, C He, L Liu, Y Zhou, Q Pu… - Thoracic …, 2015 - Wiley Online Library
Background An evaluation of cardiopulmonary exercise testing ( CPET ) screening and pre‐operative
pulmonary rehabilitation in reducing postoperative complications and improving …
pulmonary rehabilitation in reducing postoperative complications and improving …
[HTML][HTML] The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: a post hoc analysis of the ADJUVANT trial (CTONG 1104)
…, ZD Liu, S Xu, KN Chen, SD Xu, LX Liu… - Journal of Thoracic …, 2019 - Elsevier
Introduction Adjuvant gefitinib therapy prolonged disease-free survival in patients with
resected early-stage EGFR-mutation positive NSCLC in the ADJUVANT study (CTONG 1104). …
resected early-stage EGFR-mutation positive NSCLC in the ADJUVANT study (CTONG 1104). …
[HTML][HTML] ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma
…, R Ma, JK Zhou, CL Guo, YS Wang, ZG Li, LX Liu… - Scientific reports, 2016 - nature.com
Currently, there is no reliable biomarker to clinically predict the prognosis of lung adenocarcinoma
(ADC). The receptor-tyrosine-kinase like orphan receptor 1 (ROR1) is reported to be …
(ADC). The receptor-tyrosine-kinase like orphan receptor 1 (ROR1) is reported to be …
Radiotherapy, lobectomy or sublobar resection? A meta-analysis of the choices for treating stage I non-small-cell lung cancer
…, PZ Ni, G Li, XY Yang, YD Lin, LX Liu - European Journal of …, 2017 - academic.oup.com
Whether stereotactic ablative radiotherapy (SABR) is comparable to surgery in treating
stage I non-small-cell lung cancer (NSCLC) is unknown. Therefore, we conducted this meta-…
stage I non-small-cell lung cancer (NSCLC) is unknown. Therefore, we conducted this meta-…
[HTML][HTML] Albumin-to-alkaline phosphatase ratio as a novel prognostic indicator for patients undergoing minimally invasive lung cancer surgery: propensity score …
…, H Du, YJ Li, WB Zhang, GW Che, LX Liu - International Journal of …, 2019 - Elsevier
Objectives To evaluate prognostic significance of albumin-to-alkaline phosphatase ratio (AAPR)
for patients undergoing video-assisted thoracoscopic surgery (VATS) lobectomy for non-…
for patients undergoing video-assisted thoracoscopic surgery (VATS) lobectomy for non-…
Lymph node metastasis in Chinese patients with clinical T1 non‐small cell lung cancer: a multicenter real‐world observational study
…, X Li, L Liu, Y Liu, J Hu, X Fu, Y Li, Y Xu, D Liu… - Thoracic …, 2019 - Wiley Online Library
Background Approximately 8.3–15.9% of patients with clinical stage I non‐small cell lung
cancer are subsequently shown to have lymph node metastasis. However, the clinical …
cancer are subsequently shown to have lymph node metastasis. However, the clinical …
[HTML][HTML] Real-world survival outcomes based on EGFR mutation status in Chinese patients with lung adenocarcinoma after complete resection: results from the ICAN …
XN Yang, HH Yan, J Wang, XY Chu, ZD Liu… - JTO clinical and …, 2022 - Elsevier
Introduction The adjuvant treatment of patients with resected lung adenocarcinoma (LUAD)
remains unstandardized. We analyzed the survival outcomes of these patients based on …
remains unstandardized. We analyzed the survival outcomes of these patients based on …